According to the announcement, Shenghe Biological-B (02898) released its interim performance for the six months ending June 30, 2024. During this period, the group achieved other income of 1.782 million yuan (RMB, the same below), a decrease of 70.42% compared to the same period last year; research and development expenses were 37.708 million yuan, an increase of 53.22% compared to the same period last year; the loss during the period was 36.077 million yuan, a decrease of 41.33% compared to the same period last year; basic loss per share was 0.34 yuan.

The announcement stated that the decrease in other income was mainly due to the reduction in government subsidies during the reporting period. The increase in research and development expenses was mainly due to an increase in compensation to research and development staff based on shares.